Sosei Group Corp., of Tokyo, said its subsidiary, Heptares Therapeutics, has been notified by partner Teva Pharmaceutical Industries Ltd., of Petah Tikva, Israel, that a preclinical candidate calcitonin gene-related peptide antagonist has been nominated for advancement into further preclinical studies as an investigational treatment for migraine.